Magnesium Sulfate Kalceks (Magnesium Sulfate Heptahydrate)

Magnesium sulfate acts as a calcium antagonist, stabilizing cell membranes, inhibiting NMDA receptors, and reducing acetylcholine release. These actions lead to vasodilation, bronchodilation, and anticonvulsant effects, helping control seizures and restore normal magnesium balance.

The dosage of Magnesium Sulfate Kalceks is determined by the prescribing clinician based on the patient’s condition, severity, renal function, and route of administration. Healthcare professionals set the appropriate dose and infusion rate.

Magnesium sulfate is classified as a pregnancy‑category drug only when the therapeutic benefit to the mother outweighs potential fetal risk. It is commonly used in obstetric care for eclampsia. Safety during breastfeeding has not been definitively established, so clinical judgment is required.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Compared with other anticonvulsant agents, magnesium sulfate uniquely combines calcium‑antagonist activity with direct membrane stabilization, making it the preferred choice for eclampsia. Other electrolytes, such as calcium gluconate, do not provide the same seizure‑preventing properties.

Magnesium Sulfate Kalceks should be stored below 25 °C, protected from moisture and direct sunlight, and kept in its original packaging. Before use, inspect the solution for particulate matter or discoloration and ensure aseptic technique during preparation.

The product is administered by a qualified healthcare professional via intramuscular, intravenous, or subcutaneous injection. The route, infusion rate, and concentration are selected according to the clinical indication and patient’s physiological status.

Serious risks include respiratory depression, severe hypotension, cardiac arrhythmias, hypermagnesemia leading to neuromuscular blockade, and loss of deep tendon reflexes. Prompt monitoring of vital signs and serum magnesium levels is essential to mitigate these hazards.

Patients with known hypersensitivity to magnesium sulfate, severe renal failure without appropriate monitoring, or those receiving concurrent calcium‑containing IV solutions should avoid this medication unless benefits clearly outweigh risks.